Pulmonary Drug Delivery Systems Market - Latest Advancement & Future Trends (2024-2032)

Pulmonary Drug Delivery Systems Market Synopsis:

Pulmonary Drug Delivery Systems Market Size Was Valued at USD 34.36 Billion in 2023, and is Projected to Reach USD 51.95 Billion by 2032, Growing at a CAGR of 4.7 % From 2024-2032.

The pulmonary drug delivery systems market is thus defined as the portion of medical devices and delivery systems meant to depot the therapeutic agents to the lungs for the treatment of respiratory disorders. These systems enable direct and precise drug delivery principally for asthmatic, COPD and other pulmonary diseases patients. The requirements are evident in the devices discussed herein including the metered dose inhalers, DPIs and nebulizers all intended to deliver the optimized lung deposition of drugs. Pulmonary delivery systems have gaining significance as a sub-discipline in this regard because the number of respiratory diseases is increasing globally.

Most of the pulmonary drug delivery systems market is growing in a very good manner because of increasing number of respiratory diseases like asthma and COPD which are attributed to factors like pollution, smoking and changing life style. Due to a larger number of patients who look for non-systemic means of administering the drugs, the need for suitable and efficient systems have grown. Pulmonary drug delivery is another efficient route as the drug main Acts in lungs and has least systemic effect. However, advancement in the features of inhaler and nebuliser such as the tagging of sensors on smart inhalers ensures patients and clinical practitioners have better control over utilization and effectiveness of these products.

It also affects the growth of the market with references to the growing number of geriatric people since the population is vulnerable to respiratory ailments. Furthermore, there is an opportunity to witness a growth in demand by patient of pulmonary drugs delivery systems as health care infrastructure gains ground in the emerging markets. Health care organization and pharma major are keen to develop better drug delivery system to enhance the effectiveness of delivery; flexibility and affordability that have led to constant enhancement of pulmonary drug delivery system market.

Pulmonary Drug Delivery Systems Market Trend Analysis:

Increasing Adoption of Smart Inhalers

• The analysed emerging trends related to the pulmonary drug delivery systems market is the ever-increasing focus on smart inhalers. Smart inhalers are defined as the inhalers containing digital sensors that record usage by patients and transfer necessary info to a smartphone or a healthcare provider, raising probabilities of taking specific medication as prescribed with improving the patient’s health, respectively. These devices render control of the treatments feasible, and the attending physicians can intervene and review the treatment and meet the patients explaining the right usage of the inhaler. With the advancing use of connected health devices smart inhalers specifically choose popularly among the patients and healthcare organizations. Experience indicates that the more complex and analytical these gadgets are, the more demand is likely to be created for such creations in the market

Growing Demand in Emerging Markets

• The emerging economies have also pleasant proposition regarding the growth prospects of the pulmonary drug delivery systems market. In particular, the ratio of the population of the countries of the Asian-Pacific region and Latin America to exceed the era of a primarily health care expenditure and construction and the public awareness of respiratory care. When the DC’s rises in these regions along with pollution and when they are promoted to higher-level respiratory diseases act like domino effect. Governments to these regions are increasing the pace of trying to increase the availabilities of health and medical services and pharmaceutical companies are also under higher operational and growth expectations in these potentially large markets. The current growing demanded emerging markets offers an opportunity to the manufacturers to design cheap, portable and simple pulmonary drug delivery systems.

Pulmonary Drug Delivery Systems Market Segment Analysis:

Pulmonary Drug Delivery Systems Market is Segmented on the basis of Product Type, Application, Distribution Channel, and Region.

By Product Type, the Dry Powder Inhaler segment is expected to dominate the market during the forecast period

• The market segment based on Pulmonary drug delivery systems is further segmented into Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI), and it Ise SHOW that the Dry Powder Inhaler (DPI) segment occupy the largest sales proportion through the forecast period. DPIs are more preferable from the operational convenience portable DPIs and the ability of the device not to require a propellant to deliver a desired dose of the medicine, environmentally friendly. DPIs are very efficient on ailments like asthmatic and chronic obstructive pulmonary disorder, does not require synchronised inhalation hence suitable for all ages. Some of the factors which made it easy to accept DPIs are Ease, accuracy and safety of DPIs and as a technology is becoming more and more advance in future this segment of the of the market is expected to remain dominant.

By Application, the Chronic Obstructive Pulmonary Disease segment expected to held the largest share

• This market can be segmented on the basis of its application which comprises of Asthma, COPD and others out of which Chronic Obstructive Pulmonary Disease (COPD) segment should see the highest market share in the pulmonary drug delivery systems. COPD, chronic bronchitis and emphysema are leading causal agents to mortality in the world due to smoking, pollution, and constant exposure to toxic products. COPD patients require maintenances treatments for managing COPD signs and symptoms, avoiding exacerbation and improving the patients’ quality of life. Inhalers and nebulizers are fundamental equipment in COPD because those are the ways of delivering bronchodilators and steroids quickly and effectively in the lungs. If the global rate of the incidence of COPD is expected to rise, then the demand for effective pulmonary drug delivery will accordingly remain consistent.

Pulmonary Drug Delivery Systems Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America will remain the largest consumer in the global pulmonary drug delivery systems market during the forecast period because the rates of respiratory diseases are progressively increasing, the healthcare systems are well developed, and there are increased demands for innovative and efficient treatment techniques. In particular, the inhabitants of the United States have a large number of illnesses, in particular, asthma and chronic obstructive pulmonary disease, which creates great demand for efficient Pulmonary drug delivery systems. Main driving forces are high product awareness, new healthcare technologies and a vast number of usable refined advanced devices which includes the smart inhalers
•  North America market. Also, the factor of a favorable regulatory environment in North America and high investments in research and development by some players in this industry promote the improvement of new methods of drug delivery systems. Other examples of similar wearable devices have also become popular lately to manage chronic respiratory diseases and avoid frequent hospitalization in the region are Smart inhalers and wearable respiratory monitoring devices. Therefore, this emphasis in technological advancement and futuristic safety measures would help to solarize North America’s strength in the pulmonary drug delivery systems market.Cured reimbursement policies and thus successors are good healthcare policies hence setting high chances of increased demand of pulmonary drug delivery system in North America..

Active Key Players in the Pulmonary Drug Delivery Systems Market:

• 3M Health Care (United States)
• AstraZeneca (United Kingdom)
• Boehringer Ingelheim (Germany)
• Chiesi Farmaceutici S.p.A. (Italy)
• Cipla Limited (India)
• GlaxoSmithKline plc (United Kingdom)
• Koninklijke Philips N.V. (Netherlands)
• Merck & Co., Inc. (United States)
• Novartis AG (Switzerland)
• Omron Healthcare, Inc. (Japan)
• PARI GmbH (Germany)
• ResMed Inc. (United States)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Vectura Group plc (United Kingdom)
• Viatris Inc. (United States), and Other Active Players